Xinysun Instrument (Shanghai) Co., Ltd.

Solutions

Breadcrumb: Home > Solutions > Biofilm Detection

Why Must Pharmaceutical Companies Perform Biofilm Detection? Key Points on Water Systems, Cleaning Validation, and Audits

Updated:2026-11-17Views:

Biofilm risk in pharmaceutical manufacturing concentrates in the purified water and water-for-injection systems. Once a film forms on a pipe wall, a tank bottom or a valve gasket, it keeps shedding cells into the water, so microbial limits and endotoxin results exceed specification again and again in no clear pattern. Increasing the disinfectant dose usually does not help, because the problem is not insufficient strength but a film that has never been opened. This article reviews the quality and compliance risks, what the regulations require and why conventional testing misses the problem, and sets out a three-tier testing structure in which LUYOR-339 and LUYOR-330 are used to locate contamination.

The pharmaceutical industry's concern with biofilm is rooted not in the word "cleanliness" but in water. Once a biofilm forms on a pipe wall, a tank bottom or a valve gasket in a purified water or water-for-injection system, it keeps releasing cells into the water, and microbial limits and endotoxin data exceed specification repeatedly and without a clear pattern. Raising the disinfectant dose usually does not solve this, because the problem is not insufficient disinfection strength but a film that has never been opened.

1. In pharmaceutical manufacturing, the main battlefield is the water system

Biofilm needs water, a surface and time, and a pharmaceutical water system supplies all three. Pipe walls, tank bottoms and the liquid line, valves and clamp gaskets, the cold section of heat exchangers, low-velocity branches and blind ends, and the upstream and downstream sides of sampling valves are all typical high-risk positions.

Even where the system is held in circulation at 65 to 80 °C with flow kept in the turbulent range, biofilm formation cannot be assumed away. The cold end of a heat exchanger, stagnant sections during shutdown and dead zones that cleaning does not reach can all serve as starting points. Once the film is established, routine periodic disinfection only reduces the planktonic count; the population inside the film is released again after disinfection ends.

2. Four kinds of risk that biofilm creates for a manufacturer

1. Batch rejection and delayed release

A failed microbial limit, endotoxin or sterility test leads directly to batch rejection or to an investigation that delays release. The greater difficulty is that such excursions come and go, and the investigation is long and ties up a great deal of staff time.

2. Audit findings

Inspectors look not only at results but at whether the risk was identified, whether monitoring data exist, and whether effective corrective action followed. A cleaning validation that lacks a biofilm perspective is easily questioned at the point of whether disinfectant efficacy is weakened by the substrate.

3. Disinfection efficacy misjudged

The EPS of a biofilm consumes the active ingredients of a disinfectant, so the concentration actually reaching the cells is below the design value. The result is a false picture: the disinfection procedure is followed as written, the records are complete, yet validation does not deliver the expected log reduction. Raising the concentration at that point usually only raises cost and corrosion risk together.

4. Cross-contamination and product safety

Shared lines, incomplete cleaning and surfaces that CIP does not reach can all carry contamination into the next batch. The more products share a line, the harder this risk is to control by spot sampling alone.

3. What the regulations and standards require

A few documents set this out clearly:

  • EU GMP Annex 1 (2022 revision) makes the contamination control strategy (CCS) central, requires continuous monitoring of critical utilities such as water systems and evidence that the controls are effective, and names biofilm among the identified risks;
  • USP <1231> discusses biofilm formation, its hazards and control in its chapter on water systems, and stresses that periodic disinfection alone is not enough to remove an established film;
  • the annex on sterile medicinal products in China's Good Manufacturing Practice for drug products requires microbial monitoring and trend analysis of pharmaceutical water, with an investigation whenever an adverse trend appears;
  • ASTM E2799 (MBEC device), ASTM E2871 (single-tube method) and ASTM E2196 (CDC biofilm reactor) provide laboratory methods for judging whether a disinfectant actually works against biofilm, answering the question "does this disinfectant work on my film".

What these requirements have in common is the demand for evidence, and for evidence from which a trend can be read. A single passing report is far less persuasive than months of point data together with corrective action records.

4. Why conventional testing is not enough on a pharmaceutical site

The methods are not unscientific; the sampling and the time and space scales do not match:

  • a swab covers a very small area, and a sample of a few tens of square centimeters cannot represent tens of meters of piping;
  • culture takes 3 to 5 days, and by the time the result arrives the batch has long moved on;
  • testing focuses on planktonic organisms, whereas the harm from biofilm comes precisely from the attached state;
  • some organisms are viable but not culturable (VBNC) and are simply recorded as negative on a plate count.

The result is that data look satisfactory all along while the problem breaks out at one particular point in time. Closing that gap needs an on-site method that covers area, gives an immediate result and leaves image evidence.

5. A three-tier testing structure for the pharmaceutical site

TierMethodQuestion answeredTime
Routine inspectionUV-A fluorescence illumination, visual reading and photographyWhere the contamination is, and whether cleaning removed itImmediate
Point confirmationATP swabs, surface microbial samplingResidue level at that point, and whether it can be releasedSeconds to days
Laboratory confirmationCulture counts, species identification, qPCRCommunity composition, source tracing, disinfectant susceptibility1 to 5 days

Each tier has its job. Fluorescence inspection steers the limited confirmation resources to the positions that really have a problem, instead of sampling blindly along the whole line; confirmation results in turn calibrate the experience-based thresholds used in reading fluorescence. Working with only one tier means either insufficient coverage or uncontrolled cost.

6. What makes fluorescence inspection defensible

The principle is that proteins and peptides in the biofilm matrix, coenzymes and porphyrin metabolites emit visible fluorescence under UV-A excitation. The working rule on site is that green indicates an active biofilm while blue indicates non-living material such as dust and fibers. For the method to hold up in a pharmaceutical setting, a few points have to be kept:

  • A fixed route and fixed points: work from the dead-zone list and repeat the same route, so that the data can be compared;
  • A dark environment and a dry surface: dim the lighting to raise contrast, dry the surface fully and avoid reflection from a water film;
  • Wipe confirmation: where green and blue are mixed, go by the wipe result and the form; blue usually wipes clean, while green generally needs the cleaning procedure;
  • Photographic records: note the point, date, operator and severity, forming a traceable image file;
  • Controlled equipment: UV output falls with hours of use, so check it regularly with a UV radiometer and compare against historical data, avoiding false negatives caused by decay.

Handheld devices bring these points down to the level of practice. The LUYOR-339 handheld biofilm detection lamp, for example, runs on a battery for about 5 hours continuously and supports photography while scanning, so a clean area or a production line can be covered in one pass; the more compact LUYOR-330 is better suited to narrow spaces and to reaching valves and connections. The full model comparison is in the Biofilm detection lamps section.

7. Feeding the results into cleaning validation

Fluorescence data are only worth something once they enter the cleaning validation loop. In practice they can be connected like this:

At the point-selection stage, list historical excursions, structural dead zones and poorly cleaned areas in the point table, matched one to one with the swab sites. At the baseline stage, run a full-point inspection while the equipment is known to be clean, producing reference images. At the execution stage, inspect each batch or each shift along the route, judge green fluorescent points as not acceptable and send them to rework. At the re-check stage, inspect along the same route after corrective action, prove the cleaning was effective with before-and-after images, and file the images, points, dates and operators together.

The additional benefit is that when an auditor asks how you know the disinfection procedure is effective, what you produce is not a single passing number but a set of records in which the change over time can be seen.

Frequently asked questions

Can biofilm detection replace microbial limit testing of the water system?

No. Fluorescence inspection is an on-site screening method: it answers where the contamination is and whether it has been cleaned away, gives no colony count and cannot be used to release a batch. Statutory release still requires microbial limit, endotoxin and other tests under the pharmacopoeia and GMP. The relationship is one of guidance and confirmation: inspection directs sampling to the points that really have a problem, and the test results in turn verify whether the fluorescence reading is accurate.

If inspection finds green fluorescence, can the batch still be released?

Not on the fluorescence result alone. Fluorescence indicates a possible organic residue or active contamination at that point, and the deviation procedure applies: first establish whether the point is product-contact and whether it falls within cleaning coverage, then sample for microbial and endotoxin testing, and decide on release, rework or rejection in the light of the results and the product risk assessment. The fluorescence image should be filed as on-site evidence in the deviation investigation.

How is the inside of a stainless steel pipe illuminated? Must it be opened up?

The pipe does not have to be dismantled. Illumination can be introduced through existing openings such as sampling valve ports, manways, sight glasses and flange joints, checking low points, blind ends, welds and reducers first. For fully closed sections with no opening, inspection ports should be provided at the design stage, or an endoscope combined with fluorescence used; this is also why inspectability belongs in piping design for new projects.

After changing the disinfectant, does biofilm validation have to be repeated?

Re-validation is advisable. Disinfectants differ widely in their ability to penetrate EPS and to kill attached organisms, and a disinfectant that passes a planktonic laboratory test may not remove an established film. Evaluate biofilm efficacy by a method such as ASTM E2799 or E2871, then confirm the actual cleaning result with on-site fluorescence inspection; only when the two agree is the change validated.

Can UV lamps be used for inspection in grade A and B clean areas?

Yes, but the method has to be controlled. Equipment entering the area goes through the gowning and material transfer procedures and is wiped down with disinfectant; inspection is carried out with the line stopped, with no product exposed and no personnel working, to avoid raising dust and exposing people to UV. Operators must wear UV safety goggles and cover the skin. UV illumination cannot replace disinfection itself; here it is only a means of observation.

How is the effectiveness of fluorescence inspection demonstrated in an audit?

Prepare four kinds of material: a point map and list showing which risk positions are covered; baseline images showing what normal looks like; a continuous trend record showing how long the practice has run and whether the frequency has been stable; and several complete cases of fluorescence found, corrected and confirmed gone on re-check. Cases are often more persuasive than numbers, because they demonstrate both detection capability and a closed corrective loop.

Further reading: What biofilm monitoring is, and how to choose among six methods; for the operating detail see Bacterial biofilm detection: five steps and what decides the reading; for model comparison see How to choose a biofilm detection lamp.

Related sections and models

This article belongs to the Frequently asked questions section.

Other sections on the same product line include Biofilm detection lamps (UV-A excitation of biofilm autofluorescence, which makes contamination the eye cannot see visible) and Industrial test instruments (the entry point for UV inspection, rotational speed measurement, stroboscopic observation and surface inspection).

Models mentioned in this article: LUYOR-330, XEPU-1720 . Ranges, accuracy and the accessory list for each model are given on its product page.

  • Official WeChat QR code

    Email: info@xinysun.com

  • Tel: 131-2093-6518

  • Address: 1525 Minqiang Road, Bldg 26, Songjiang, Shanghai

Official WeChat QR code Follow

Official WeChat QR code

Contact

131-2093-6518

Top